Analysis of the expression and mutation of PARK2 in pan-cancer based on multiple databases

doi:10.3877/cma.j.issn.2095-123X.2021.03.003

Abstract

Abstract:

Objective

To analyze the expression and mutation of PARK2 in pan-cancer.

Methods

The tumor immune database TIMER2.0 was used to analyze the mRNA expression level of PARK2 in 33 tumors, and to investigate the potential relationship between the level of cancer-related fibroblast infiltration and PARK2 gene expression in different cancer types of The Cancer Genome Atlas (TCGA); the GEPIA database was used to obtain the overall survival and disease-free survival of PARK2 in all TCGA tumors; the cBioportal database was used to summarize the mutations of pan-cancer genes and obtain the specific mutation site information on the PARK2 functional domain map; the STRING database was used to obtain the protein interaction network of PARK2.

Results

PARK2 is highly expressed in most cancers and has a significant correlation with the prognosis of tumor patients. The expression of PARK2 was correlated with the infiltration of tumor associated fibroblasts in cervical squamous cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma. Mutations and/or deletions of PARK2 gene are also involved in the function of PARK2.

Conclusion

The pan-cancer analysis of PARK2 showed that PARK2 expression was statistically correlated with clinical prognosis, immune invasion, etc., which will help to understand the role of in tumorigenesis from the perspective of clinical tumor samples and provide a potential targeted therapeutic strategy for the treatment of multiple cancers.

Key words: PARK2, Pan-cancer, Prognosis, Gene mutation, Immune infiltration

Ya’nan Dou, Xiaowei Fei, Jialiang Wei, Zhou Fei. Analysis of the expression and mutation of PARK2 in pan-cancer based on multiple databases[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2021, 11(03): 139-146.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2021.03.003

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2021/V11/I03/139

Figures/Tables 5

References 18

[1]	Cui X, Zhang X, Liu M, et al. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors[J]. Genomics, 2020, 112(6): 3958-3967.
[2]	Ihle NT, Abraham RT. The Pten-Parkin axis: at the nexus of cancer and neurodegeneration[J]. Molecular Cell, 2017, 65(6): 959-960.
[3]	Poulogiannis G, McIntyre RE, Dimitriadi M, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice[J]. Proc Natl Acad Sci USA, 2010, 107(34): 15145-15150.
[4]	Xiong D, Wang Y, Kupert E, et al. A recurrent mutation in PARK2 is associated with familial lung cancer[J]. Am J Hum Genet, 2015, 96(2): 301-308.
[5]	Li C, Zhang Y, Cheng X, et al. PINK1 and PARK2 suppress pancreatic tumorigenesis through control of mitochondrial iron-mediated immunometabolism[J]. Dev Cell, 2018, 46(4): 441-455.e8.
[6]	Lin DC, Xu L, Chen Y, et al. Genomic and functional analysis of the E3 ligase PARK2 in glioma[J]. Cancer Res, 2015, 75(9): 1815-1827.
[7]	Zhang ZL, Wang NN, Ma QL, et al. Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells[J]. Acta Pharmacol Sin, 2020, 41(1): 93-100.
[8]	Zhou X, Li Y, Wang W, et al. Regulation of Hippo/YAP signaling and esophageal squamous carcinoma progression by an E3 ubiquitin ligase PARK2[J]. Theranostics, 2020, 10(21): 9443-9457.
[9]	Lei Z, Duan H, Zhao T, et al. PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway[J]. Cell Death Dis, 2018, 9(3): 375.
[10]	Duan H, Lei Z, Xu F, et al. PARK2 suppresses proliferation and tumorigenicity in non-small cell lung cancer[J]. Front Oncol, 2019, 9: 790.
[11]	Chen H, Li Y, Li Y, et al. PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity via degradation of phospho-BCL-2[J]. Theranostics, 2020, 10(22): 9984-10000.
[12]	Xu L, Lin DC, Yin D, et al. An emerging role of PARK2 in cancer[J]. J Mol Med (Berl), 2014, 92(1): 31-42.
[13]	Sun X, Liu M, Hao J, et al. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation[J]. Cell Cycle, 2013, 12(7): 1133-1141.
[14]	Editorial expression of concern: parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27[J]. Proc Natl Acad Sci USA, 2017, 114(16): E3364.
[15]	Ikeuchi K, Marusawa H, Fujiwara M, et al. Attenuation of proteolysis-mediated cyclin e regulation by alternatively spliced parkin in human colorectal cancers[J]. Int J Cancer, 2009, 125(9): 2029-2035.
[16]	Agirre X, Román-Gómez J, Vázquez I, et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia[J]. Int J Cancer, 2006, 118(8): 1945-1953.
[17]	Denison SR, Wang F, Becker NA, et al. Alterations in the common fragile site gene parkin in ovarian and other cancers[J]. Oncogene, 2003, 22(51): 8370-8378.
[18]	Denison SR, Callahan G, Becker NA, et al. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer[J]. Genes Chromosomes Cancer, 2003, 38(1): 40-52.

Please choose a citation manager

Content to export